Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655324 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT06655324: Recruiting Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.
NCT06655324 is a Phase 1 study of Healthy that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 200 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06655324, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection site AEs will be recorded on a vaccination report card (VRC).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL V350A
- BIOLOGICAL V350B
Study Locations (9)
Missouri
- Alliance for Multispecialty Research, LLC ( Site 0008) - Kansas City
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016) - Springfield
Nebraska
- Velocity Clinical Research Lincoln ( Site 0004) - Lincoln
- Velocity Clinical Research, Omaha ( Site 0005) - Omaha
California
- California Clinical Trials Medical Group managed by PAREXEL ( Site 0011) - Glendale
Florida
- QPS-MRA, LLC ( Site 0012) - Miami
Ohio
- Remington-Davis, Inc. ( Site 0017) - Columbus
Oklahoma
- Lynn Health Science Institute ( Site 0010) - Oklahoma City
Tennessee
- Alliance for Multispecialty Research, LLC ( Site 0009) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2028-07-17 |
| Phase | Phase 1 |
What NCT06655324 shows while recruiting
NCT06655324 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06655324 lists 9 locations in 7 states (Missouri, Nebraska, California).
Frequently Asked Questions
What is clinical trial NCT06655324 about?
NCT06655324 is a clinical study titled "A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).". Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this s...
What is the current status of trial NCT06655324?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2024-12-05. Estimated completion is 2028-07-17.
What conditions does trial NCT06655324 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT06655324?
The interventions under investigation include: Placebo (BIOLOGICAL), V350A (BIOLOGICAL), V350B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06655324?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06655324 being conducted?
This trial has 9 study locations across California, Florida, Missouri, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06655324's enrollment target sits among peer trials
200 118th of 1090 higher than 965 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI